{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:15:13Z","timestamp":1781324113107,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"vor","delay-in-days":1063,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2012]]},"DOI":"10.1111\/1469-0691.12012","type":"journal-article","created":{"date-parts":[[2012,8,31]],"date-time":"2012-08-31T05:33:09Z","timestamp":1346391189000},"page":"28-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"S6","title":["Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?"],"prefix":"10.1016","volume":"18","author":[{"given":"O.A.","family":"Cornely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/1469-0691.12012_bib1","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1086\/587654","article-title":"The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection","volume":"46","author":"Bartlett","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12012_bib2","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1469-0691.2009.03099.x","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI)","volume":"15","author":"Bauer","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/1469-0691.12012_bib3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2147\/TCRM.S3145","article-title":"New advances in the treatment of Clostridium difficile infection (CDI)","volume":"4","author":"Hedge","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1111\/1469-0691.12012_bib4","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1517\/13543784.2010.495386","article-title":"Future novel therapeutic agents for Clostridium difficile infection","volume":"19","author":"Koo","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/1469-0691.12012_bib5","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity","volume":"45","author":"Zar","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1111\/1469-0691.12012_bib6","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1086\/521860","article-title":"Owens RC Jr. Treatment of Clostridium difficile infection","volume":"46","author":"Gerding","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12012_bib7","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/j.1572-0241.2002.05839.x","article-title":"Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease","volume":"97","author":"McFarland","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/1469-0691.12012_bib8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMoa0907635","article-title":"Treatment with monoclonal antibodies against Clostridium difficile toxins","volume":"362","author":"Lowy","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/1469-0691.12012_bib9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/1469-0691.12012_bib10","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1001\/jama.1994.03510480037031","article-title":"A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease","volume":"271","author":"McFarland","year":"1994","journal-title":"JAMA"},{"key":"10.1111\/1469-0691.12012_bib11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1473-3099(05)70215-2","article-title":"Treatment of Clostridium difficile-associated disease: old therapies and new strategies","volume":"5","author":"Aslam","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/1469-0691.12012_bib12","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jac\/dkn313","article-title":"Emergence of reduced susceptibility to metronidazole in Clostridium difficile","volume":"62","author":"Baines","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/1469-0691.12012_bib13","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrmicro2164","article-title":"Clostridium difficile infection: new developments in epidemiology and pathogenesis","volume":"7","author":"Rupnik","year":"2009","journal-title":"Nature Rev Microbiol"},{"key":"10.1111\/1469-0691.12012_bib14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1056\/NEJMe1013236","article-title":"The search for effective treatment of Clostridium difficile infection","volume":"364","author":"DuPont","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/1469-0691.12012_bib15","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1128\/AAC.05647-11","article-title":"Prospective observational study comparing three different treatment regimens in patients with Clostridium difficile infection","volume":"56","author":"Wenisch","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12012_bib16","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1099\/jmm.0.028571-0","article-title":"Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile","volume":"60","author":"Huhulescu","year":"2011","journal-title":"J Med Microbiol"},{"key":"10.1111\/1469-0691.12012_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/MPG.0b013e3181a118c6","article-title":"Clostridium difficile infections: emerging epidemiology and new treatments","volume":"48","author":"Cohen","year":"2009","journal-title":"J Ped Gastroenterol Nutr"},{"key":"10.1111\/1469-0691.12012_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0140-6736(10)61266-4","article-title":"Clostridium difficile infection in Europe: a hospital-based survey","volume":"377","author":"Bauer","year":"2011","journal-title":"Lancet"},{"key":"10.1111\/1469-0691.12012_bib19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(00)03592-3","article-title":"Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea","volume":"357","author":"Kyne","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/1469-0691.12012_bib20","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1053\/j.gastro.2008.12.038","article-title":"Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection","volume":"136","author":"Hu","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1111\/1469-0691.12012_bib21","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/430315","article-title":"Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada","volume":"40","author":"P\u00e9pin","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12012_bib22","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1099\/jmm.0.029470-0","article-title":"Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile","volume":"60","author":"Babakhani","year":"2011","journal-title":"J Med Microbiol"},{"key":"10.1111\/1469-0691.12012_bib23","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/AAC.01443-07","article-title":"OPT-80 Eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection","volume":"53","author":"Louie","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12012_bib24","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1099\/mic.0.042010-0","article-title":"A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin","volume":"156","author":"Tannock","year":"2010","journal-title":"Microbiology"},{"key":"10.1111\/1469-0691.12012_bib25","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1128\/AAC.00104-11","article-title":"Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile","volume":"55","author":"Babakhani","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12012_bib26","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1586\/eri.11.53","article-title":"Fidaxomicin: first-in-class macrocyclic antibiotic","volume":"9","author":"Mullane","year":"2011","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Suppl 2","key":"10.1111\/1469-0691.12012_bib27","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1086\/516247","article-title":"Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection","volume":"25","author":"Gerding","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12012_bib28","series-title":"Committee for Medicinal Products for Human Use (CHMP) Assessment report for DIFICLIR (fidaxomicin)","year":"2011"},{"key":"10.1111\/1469-0691.12012_bib29","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1128\/AAC.01045-07","article-title":"Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses","volume":"52","author":"Shue","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/1469-0691.12012_bib30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 2","key":"10.1111\/1469-0691.12012_bib31","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1093\/cid\/cis499","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials","volume":"55","author":"Crook","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12012_bib32","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/cid\/cis430","article-title":"Decreased cure rate and increased recurrence rate for Clostridium difficile infection caused by the epidemic C. difficile BI strain","volume":"55","author":"Petrella","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1111\/1469-0691.12012_bib33","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1093\/cid\/cis462","article-title":"Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin","volume":"55","author":"Cornely","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12012_bib34","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/cid\/cir404","article-title":"Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in patients taking concomitant antibiotics for other concurrent infections","volume":"53","author":"Mullane","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1111\/1469-0691.12012_bib35","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1093\/ndt\/13.11.2842","article-title":"Clostridium difficile colitis associated with chronic renal failure","volume":"13","author":"Cunney","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/1469-0691.12012_bib36","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/gut.27.10.1169","article-title":"Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile","volume":"27","author":"Bolton","year":"1986","journal-title":"Gut"},{"key":"10.1111\/1469-0691.12012_bib37","first-page":"921","article-title":"Clostridium difficile-associated diarrhea","volume":"71","author":"Schroeder","year":"2005","journal-title":"Am Fam Physician"},{"key":"10.1111\/1469-0691.12012_bib38","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ajg.2012.60","article-title":"Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection","volume":"107","author":"Brandt","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/1469-0691.12012_bib39","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1056\/NEJM200002103420604","article-title":"Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A","volume":"342","author":"Kyne","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/1469-0691.12012_bib40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1099\/jmm.0.45753-0","article-title":"Alternative treatment for Clostridium difficile disease: what really works","volume":"54","author":"McFarland","year":"2005","journal-title":"J Med Microbiol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14608454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14608454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:13:07Z","timestamp":1761117187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14608454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":40,"alternative-id":["S1198743X14608454"],"URL":"https:\/\/doi.org\/10.1111\/1469-0691.12012","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2012]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/1469-0691.12012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}